As outlined above, research has identified Src as a crucial activator of the ERK1/2 pathway in primary uveal melanoma (UM), indicating potential for Src inhibition as a treatment strategy in primary UM [26]. This evidence concerns the gene MAPK3 and uveal melanoma.